LENSAR (LNSR) vs Lucid Diagnostics (LUCD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lucid Diagnostics (LUCD) has outperformed LENSAR (LNSR) over the past year, losing 46.7% versus a loss of 47.0%. Over five years, LNSR leads with a -14.2% price change compared with -93.0% for LUCD. Lucid Diagnostics is the larger company by market cap ($121.8 million vs $78.3 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LNSR | LUCD |
|---|---|---|
| Share price | $6.37 | $0.638 |
| Market cap | $78.26M | $121.83M |
| 1-day change | -1.24% | -1.86% |
| YTD return | -44.54% | -40.36% |
| 1-year return | -47.04% | -46.71% |
| 5-year return | -14.23% | -93.05% |
| P/E ratio (TTM) | 35.39 | — |
| EPS (TTM) | $0.18 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.94 | $1.63 |
| 52-week low | $4.95 | $0.50 |
| Distance from 52-week high | -50.77% | -60.83% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +77.86% | +526.96% |
| Average volume | 102.04K | 1.35M |
| Shares outstanding | 12.29M | 190.95M |
| Employees | 150 | 82 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About LENSAR
LNSR stock →LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision.
Health Care · Medical/Dental Instruments · 150 employees
About Lucid Diagnostics
LUCD stock →Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.
Health Care · Medical/Dental Instruments · 82 employees
LNSR vs LUCD FAQ
Which is bigger, LENSAR or Lucid Diagnostics?
Lucid Diagnostics (LUCD) is larger, with a market capitalization of $121.83M compared with $78.26M for LENSAR (LNSR).
Which stock has performed better over the past year, LNSR or LUCD?
LUCD returned -46.71% over the past 12 months, compared with -47.04% for LNSR (price return, excluding dividends). Past performance does not predict future results.
Are LENSAR and Lucid Diagnostics in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.